Abstract
Imatinib should continue to be the front-line therapy for patients who have newly diagnosed chronic myelogenous leukemia accompanied by close monitoring. Patients should switch to a second-generation tyrosine kinase inhibitor at the earliest sign of resistance or suboptimal response to imatinib.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 234-237 |
| Number of pages | 4 |
| Journal | Cancer |
| Volume | 117 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 15 2011 |
ASJC Scopus subject areas
- Oncology
- Cancer Research